O
ODTC
vs
S&P 500
S&P 500
Over the past 12 months, ODTC has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +14% growth.
Stocks Performance
ODTC vs S&P 500
Performance Gap
ODTC vs S&P 500
Performance By Year
ODTC vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Odonate Therapeutics Inc
Glance View
Odonate Therapeutics, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improves and extends the lives of patients with cancer. The company is headquartered in New York City, New York and currently employs 137 full-time employees. The company went IPO on 2017-12-07. The firm is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. The company is focused on the development of tesetaxel, a novel chemotherapy agent. The company has completed Phase-II studies in patients with metastatic breast cancer (MBC). The firm's tesetaxel can be administered orally with a low pill burden and dosing regimen. Taxanes destroy cancer cells by preventing them from entering mitosis and thereby leading to apoptosis (cell death).
